Comparative effect of statins on the risk of incident Alzheimer disease
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To investigate whether fungus-derived statins are associated with a lower risk of incident Alzheimer disease (AD) compared with synthetic statins using real-world clinical practice data. METHODS: We identified a population-based retrospective cohort of patients aged ≥60 years newly prescribed a statin between January 1, 1994, and December 31, 2012, and followed until March 31, 2015, using the UK Clinical Practice Research Datalink. Statins were consecutively classified according to their type, lipophilicity, and potency. For each group, we calculated the crude AD incidence rates per 1,000 person-years. Time-dependent Cox proportional hazards models adjusted for propensity score deciles were used to estimate hazard ratios (HRs) with 95% confidence interval (CIs) of incident AD associated with different statin categories. RESULTS: Over the 18-year study period, we identified 465,085 statin users, including 7,669 patients who developed AD during 2,891,268 person-years of follow-up (incidence rate 2.65 [95% CI 2.59-2.71] per 1,000 person-years). Compared to synthetic, fungus-derived statins were associated with an increased risk of AD (HR 1.09, 95% CI 1.03-1.15). Lipophilic statins also were associated with higher AD risk (HR 1.18, 95% CI 1.09-1.27) compared to hydrophilic statins, while statin potency did not modify the risk of AD (adjusted HR 1.03, 95% CI 0.98-1.08). The risk was further reduced in sensitivity analyses. CONCLUSION: Fungus-derived and lipophilic statins were not associated with decreased incidence of AD compared to synthetic and hydrophilic statins. The modest variations in the risk of incident AD observed between statin characteristics needs to be evaluated in future studies on their possible heterogeneous neuroprotective effect.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Shepherd, J., Blauw, G. J., Murphy, M. B., Bollen, E. L., Buckley, B. M., Cobbe, S. M., Ford, I., Gaw, A., Hyland, M., Jukema, J. W., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)11600-x · Cited by 3,378
Data Resource Profile: Clinical Practice Research Datalink (CPRD)
Herrett, E., Gallagher, A. M., Bhaskaran, K., Forbes, H., Mathur, R., van Staa, T., & Smeeth, L. (2015) · International Journal of Epidemiology · doi:10.1093/ije/dyv098 · Cited by 2,667 · cited 2×
“It represents the UK general population by age, sex, and ethnicity.(17) Participating practices routinely collect the data as a part of the clinical care, and transfer the anonymized information to the CPRD monthly.”
BackgroundValidation and validity of diagnoses in the General Practice Research Database: a systematic review
Herrett, E., Thomas, S. L., Schoonen, W. M., Smeeth, L., & Hall, A. J. (2010) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2009.03537.x · Cited by 1,109
Statins for the prevention of dementia
McGuinness, B., Craig, D., Bullock, R., & Passmore, P. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003160.pub3 · Cited by 490
Haag, M. D. M., Hofman, A., Koudstaal, P. J., Stricker, B. H. C., & Breteler, M. M. B. (2009) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2008.150433 · Cited by 393 · cited 2×
“Some of these studies defined their exposure as a combination of several statins assuming a class effect in neuroprotection,(3,5,7,8) while others grouped statins by their lipophilic properties.(4,6,10,28) In a subsequent meta-analysis,(29) the pooled results from 20 observational studies suggested some association be…”
BackgroundResultNaci, H., Brugts, J., & Ades, T. (2013) · Circulation: Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.111.000071 · Cited by 292 · cited 1×
“Second, statins were grouped by potency as those with high/medium potency (atorvastatin >40 mg, rosuvastatin >10 mg, simvastatin >40 mg/fluvastatin >40 mg, simvastatin <10–40 mg, atorvastatin ≤40 mg, rosuvastatin ≤10 mg) and low potency (fluvastatin ≤40 mg, pravastatin ≤20 mg, simvastatin ≤10 mg).(24) Daily dosage was…”
MethodStatins, cognition, and dementia-systematic review and methodological commentary
Power, M. C., Weuve, J., Sharrett, A. R., Blacker, D., & Gottesman, R. F. (2015) · Nature Reviews Neurology · doi:10.1038/nrneurol.2015.35 · Cited by 150 · cited 1×
“Some studies reporting a protective effect of statins against dementia may be susceptible to reverse causation or indication bias.(31) In contrast, 2 randomized controlled trials reported on the lack of neuroprotective effects of statins among their secondary endpoints.”
ResultImfeld, P., Brauchli Pernus, Y. B., Jick, S. S., & Meier, C. R. (2013) · Journal of Alzheimer's Disease · doi:10.3233/jad-121819 · Cited by 72
Cited by
Statin Toxicity: Mechanistic Insights and Clinical Implications
Ward, N. C., Watts, G. F., & Eckel, R. H. (2019) · Circulation Research · doi:10.1161/circresaha.118.312782 · Cited by 757
Schultz, B. G., Patten, D. K., & Berlau, D. J. (2018) · Translational Neurodegeneration · doi:10.1186/s40035-018-0110-3 · Cited by 229
“A recent comparative effectiveness study investigated whether fungus-derived statins are associated with an lower risk of incident AD compared with synthetic statins [50].”
BackgroundNew therapeutics beyond amyloid-β and tau for the treatment of Alzheimer’s disease
Zhang, F., Zhong, R.-J., Cheng, C., Li, S., & Le, W.-D. (2021) · Acta Pharmacologica Sinica · doi:10.1038/s41401-020-00565-5 · Cited by 105
Petek, B., Häbel, H., Xu, H., Villa-Lopez, M., Kalar, I., Hoang, M. T., Maioli, S., Pereira, J. B., Mostafaei, S., Winblad, B., et al. (2023) · Alzheimer's Research & Therapy · doi:10.1186/s13195-023-01360-0 · Cited by 65
Infectious Disease Burden and the Risk of Alzheimer’s Disease: A Population-Based Study
Douros, A., Santella, C., Dell’Aniello, S., Azoulay, L., Renoux, C., Suissa, S., & Brassard, P. (2021) · Journal of Alzheimer's Disease · doi:10.3233/jad-201534 · Cited by 37
“We defined Alzheimer’s disease based on a modified algorithm initially developed and validated by Imfeld and colleagues [21], which has previously been used by our group [22].”
Self-citation
Metadata
- Authors
- Sinyavskaya, L., Gauthier, S., Renoux, C., Dell'Aniello, S., Suissa, S., & Brassard, P.
- Venue
- Neurology
- Published
- 2018-01-16
- Volume
- 90
- Issue
- 3
- Pages
- e179-e187
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- OpenAlex
- W2775023944
- Cited by
- 39
- References
- 8
- FWCI
- 4.04
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Comparative effect of statins on the risk of incident Alzheimer disease. https://app.cochat.ai/papers/10.1212/wnl.0000000000004818
- The paper
- Sinyavskaya, L., Gauthier, S., Renoux, C., Dell'Aniello, S., Suissa, S., & Brassard, P. (2018). Comparative effect of statins on the risk of incident Alzheimer disease. Neurology. https://doi.org/10.1212/wnl.0000000000004818
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.